GSK-3β, a double-edged sword in Nrf2 regulation: Implications for neurological dysfunction and disease [version 1; referees: 2 approved]

Michael Aschner, Megan Culbreth

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

In the past decade, it has become evident that glycogen synthase kinase 3β (GSK-3β) modulates the nuclear factor erythroid 2-related factor 2 (Nrf2) oxidative stress response. GSK-3β functions as an inhibitor, both directly in the activation and indirectly in the post-induction of Nrf2. The incidence of oxidative stress in neurological dysfunction and disease has made this signaling pathway an attractive therapeutic target. There is minimal evidence, however, to support a distinctive function for GSK-3β mediated Nrf2 inhibition in nervous system decline, apart from the typical oxidative stress response. In both Alzheimer's disease and brain ischemia, this pathway has been explored for potential benefits on disease etiology and advancement. Presently, it is unclear whether GSK-3β mediated Nrf2 inhibition markedly influences these disease states. Furthermore, the potential that each has unique function in neurodegenerative decline is unsubstantiated.

Original languageEnglish (US)
Article number1043
JournalF1000Research
Volume7
DOIs
StatePublished - Jan 1 2018

Fingerprint

Glycogen Synthase Kinase 3
Oxidative stress
Oxidative Stress
Neurology
Brain Ischemia
Nervous System
Brain
Alzheimer Disease
Chemical activation
Incidence
Inhibition (Psychology)

Keywords

  • GSK-3β
  • Nrf2
  • Oxidative stress

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

GSK-3β, a double-edged sword in Nrf2 regulation : Implications for neurological dysfunction and disease [version 1; referees: 2 approved]. / Aschner, Michael; Culbreth, Megan.

In: F1000Research, Vol. 7, 1043, 01.01.2018.

Research output: Contribution to journalReview article

@article{09ab29ea58bd424593aff42d2f391cd8,
title = "GSK-3β, a double-edged sword in Nrf2 regulation: Implications for neurological dysfunction and disease [version 1; referees: 2 approved]",
abstract = "In the past decade, it has become evident that glycogen synthase kinase 3β (GSK-3β) modulates the nuclear factor erythroid 2-related factor 2 (Nrf2) oxidative stress response. GSK-3β functions as an inhibitor, both directly in the activation and indirectly in the post-induction of Nrf2. The incidence of oxidative stress in neurological dysfunction and disease has made this signaling pathway an attractive therapeutic target. There is minimal evidence, however, to support a distinctive function for GSK-3β mediated Nrf2 inhibition in nervous system decline, apart from the typical oxidative stress response. In both Alzheimer's disease and brain ischemia, this pathway has been explored for potential benefits on disease etiology and advancement. Presently, it is unclear whether GSK-3β mediated Nrf2 inhibition markedly influences these disease states. Furthermore, the potential that each has unique function in neurodegenerative decline is unsubstantiated.",
keywords = "GSK-3β, Nrf2, Oxidative stress",
author = "Michael Aschner and Megan Culbreth",
year = "2018",
month = "1",
day = "1",
doi = "10.12688/f1000research.15239.1",
language = "English (US)",
volume = "7",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - GSK-3β, a double-edged sword in Nrf2 regulation

T2 - Implications for neurological dysfunction and disease [version 1; referees: 2 approved]

AU - Aschner, Michael

AU - Culbreth, Megan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In the past decade, it has become evident that glycogen synthase kinase 3β (GSK-3β) modulates the nuclear factor erythroid 2-related factor 2 (Nrf2) oxidative stress response. GSK-3β functions as an inhibitor, both directly in the activation and indirectly in the post-induction of Nrf2. The incidence of oxidative stress in neurological dysfunction and disease has made this signaling pathway an attractive therapeutic target. There is minimal evidence, however, to support a distinctive function for GSK-3β mediated Nrf2 inhibition in nervous system decline, apart from the typical oxidative stress response. In both Alzheimer's disease and brain ischemia, this pathway has been explored for potential benefits on disease etiology and advancement. Presently, it is unclear whether GSK-3β mediated Nrf2 inhibition markedly influences these disease states. Furthermore, the potential that each has unique function in neurodegenerative decline is unsubstantiated.

AB - In the past decade, it has become evident that glycogen synthase kinase 3β (GSK-3β) modulates the nuclear factor erythroid 2-related factor 2 (Nrf2) oxidative stress response. GSK-3β functions as an inhibitor, both directly in the activation and indirectly in the post-induction of Nrf2. The incidence of oxidative stress in neurological dysfunction and disease has made this signaling pathway an attractive therapeutic target. There is minimal evidence, however, to support a distinctive function for GSK-3β mediated Nrf2 inhibition in nervous system decline, apart from the typical oxidative stress response. In both Alzheimer's disease and brain ischemia, this pathway has been explored for potential benefits on disease etiology and advancement. Presently, it is unclear whether GSK-3β mediated Nrf2 inhibition markedly influences these disease states. Furthermore, the potential that each has unique function in neurodegenerative decline is unsubstantiated.

KW - GSK-3β

KW - Nrf2

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85050280306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050280306&partnerID=8YFLogxK

U2 - 10.12688/f1000research.15239.1

DO - 10.12688/f1000research.15239.1

M3 - Review article

C2 - 30079246

AN - SCOPUS:85050280306

VL - 7

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 1043

ER -